Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age ≥ 18 years~* Able to sign an informed consent form~* Advanced and/or metastatic colorectal cancer~* Colorectal cancer with KRAS wild type genotype~* At least one unidimensionally measurable lesion according to RECIST criteria (1.1 revised) (to be assessed ≤ 28 days prior to the study treatment)~* All patients with the following features will be included:~  1. Progression free survival \> 6 months after adjuvant treatment +/- radiotherapy~ 2. De novo diagnosis of the disease~* Performance ECOG status of 0-2~* Life expectancy ≥ 3 months~* Adequate bone marrow function: neutrophils ≥1,5 x 10\^9/L; platelets ≥ 100 x 10\^9/L; hemoglobin ≥9 g/dL.~* Adequate liver, renal and hematological function as follows:~  1. Adequate liver function: SGOT and SGPT 2.5 x ULN (5 x ULN in case of hepatic metastasis). Total bilirubin \< 1,5 x ULN. Alkaline phosphatase 2,5 x LSN (5 x ULN if hepatic metastasis or 10 x ULN if bone metastasis)~ 2. Creatinine clearance or creatinine clearance during 24 hours ≥ 50 mL/min~ 3. Magnesium ≥ LLN, calcium ≥ LLN~Exclusion Criteria:~* PS \> 2 or elderly patients with fragility criteria~* Previous surgery for metastasis~* Previous systemic treatment for the metastatic colorectal cancer~* Previous treatment with antibodies anti-EGFR or treatment with small-molecule EGFR tyrosine kinase inhibitors or EGFR signal transduction inhibitors. Subjects who suspend their first dose due to a reaction to the infusion can participate~* Central nervous system metastasis (except: treated subjects with asymptomatic CNS metastasis who have not received steroids within the 30 days prior to inclusion)~* Prior malignant tumor in the last 5 years, except: basal cell carcinoma of the skin or pre-invasive cervical cancer~* Unresolved toxicities from a prior systemic treatment which do not qualify the patient for inclusion~* Presence of peripheral neuropathy (degree \> 1 in the ctc version 3.0) and serious nonhealing wound, ulcer, or bone fracture~* Hormonal treatment, immunotherapy or experimental or approved antibodies/proteins ≤ 30 days before the inclusion~* Uncontrolled serious cardiovascular disease or: congestive cardiac failure NYHA lll or lV, unstable angina pectoris, myocardial infarction precedents in the past 12 months, significant arrhythmias~* Interstitial pneumonitis or pulmonary fibrosis precedents, or interstitial pneumonitis or pulmonary fibrosis signs on the thoracic CT-scan~* Treatment for systemic infection within the 14 days prior to treatment~* Acute/subacute intestinal occlusion and/or active inflammatory bowel disease or any other bowel disease producing chronic diarrhea~* Precedent of Gilbert's syndrome or dihydropyrimidine dehydrogenase deficiency~* Precedent of any disease which can increase the risks associated to the participation in the study or interfere in the study results~* Known positive test for the following infections: HIV, Hepatitis C + abnormal liver enzymes values, active chronic Hepatitis B (except Hepatitis C seropositive with normal liver enzymes)~* All concurrent diseases which can increase the toxicity risk~* The individual presents a disorder of any kind which jeopardizes their ability to give their written consent form and/or fulfill the study procedures~* Any investigational agent within 30 days before enrolment~* Pregnant or breastfeeding woman, or planning to get pregnant within the 6 months after treatment~* Surgery (excluding the diagnostic biopsy or placing of a central venous catheter)~* Woman or man of childbearing potential not consenting to use adequate contraceptive precautions during the study and 6 months after de last administration for women, and 1 month for men~* Unability to fulfill the study requirements by the patients~* Psychological, family, sociological or geographical conditions that may interfere with the fulfillment of the study protocol and the follow-up calendar

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FOLFIRI (m) or FOLFOX-6 (m) + cetuximab (Type: EXPERIMENTAL): FOLFOX/FOLFIRI + cetuximab 500mg/m2 bi-weekly for 6 months, then bi-weekly cetuximab as monotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).